CombiGene AB (publ): Nominating committee
The nominating committee has been constituted in accordance with the resolution adopted by the annual general meeting (“AGM”) 2021
The AGM 2021 resolved that a nominating committee should be appointed in accordance with the following: “The nominating committee shall consist of representatives for the three largest shareholders in terms of votes as of 30 September 2021. If any of these shareholders refrains from appointing a representative, the following shareholders shall, in the order of magnitude, be given the opportunity to appoint a representative until three members have been appointed. The names of the members in the nominating committee must be published by the company no later than six months before the AGM in 2022. The shareholder representative who represents the largest shareholder, shall be appointed chairman of the nominating committee, unless the nominating committee decides otherwise”.
The nominating committee has been constituted in accordance with the resolution adopted by the AGM 2021. The nominating committee consists of Ivar Nordqvist, Arne Ferstad and Marcus Isaksson representing Thoren Tillväxt AB.
The nominating committee’s tasks include submitting proposals to the AGM regarding:
• Chairman of the AGM
• Election of board members
• Chairman of the board of directors
• Remuneration to the board of directors including the chairman
• Election of auditor and remuneration to the auditor
• Rules of procedure for the nominating committee
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.